A Biological Basis for Repair of the ACL
ACL 修复的生物学基础
基本信息
- 批准号:7291625
- 负责人:
- 金额:$ 30.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-25 至 2010-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenovirus VectorAdenovirusesAdherent CultureAnimalsAnterior Cruciate LigamentArchitectureArthritisBMP-12BiologicalBiologyBiomechanicsCell divisionCell surfaceCellsClinicalClinical TrialsCollagenConditionDataDefectDevelopmentElementsEnvironmentFailureFamily suidaeFibroblast Growth Factor 2FibroblastsFluorescence-Activated Cell SortingFutureGene TransferGenesGrowth FactorGrowth Factor GeneHealedHistologyHumanHydrogelsImmunohistochemistryIn SituIn VitroInjuryKneeKnowledgeLaboratoriesLigamentsLocationMagnetic Resonance ImagingMarrowMechanicsMediatingMesenchymal Stem CellsMethodsModelingMorbidity - disease rateNumbersOperative Surgical ProceduresOrthopedicsOutcomePatientsPhenotypePopulationProductionPropertyPurposeRecombinant Growth FactorRecombinant ProteinsRecombinantsResearchResearch PersonnelRuptureSiteSurgical suturesSus scrofaSystemTestingThickTimeTissuesTranslatingUrsidae FamilyWeekWound HealingbasecaN protocolcell injurycell motilityclinically relevantcostexperiencehealinghuman TGFB1 proteinimplantationimprovedin vivoin vivo Modelinjuredinjury and repairkinematicsmigrationmonolayernovelreconstructionrepairedresearch studyresponseresponse to injuryscaffoldsuccesstissue regenerationvector
项目摘要
DESCRIPTION (provided by applicant): Rupture of the anterior cruciate ligament (ACL) occurs in over 100,000 patients each year. It cannot heal spontaneously. As neither surgical repair nor non-surgical treatments provide a reliably satisfactory clinical outcome, ACL ruptures remain a pressing orthopaedic problem. The research described in this proposal is directed towards improving the repair of the ACL through the application of novel biological approaches. These are based upon recent data suggesting that, contrary to the received view, the ruptured ACL mounts a healing response when a reinforced collagenous hydrogel is interposed between the severed ends of the ligament. Critical to this response is the migration of cells from the damaged ligament into the hydrogel. Preliminary data suggest that these are not representative of ACL cells as a whole, but constitute a distinct population which shares many of the properties of mesenchymal stem cells (MSCs). To achieve a clinically useful repair, these cells must divide, differentiate into ligament cells and lay down a matrix of sufficient mechanical strength. The experiments described in this proposal address these fundamental issues using in vitro and in vivo porcine models. In Specific Aim 1, the cells that migrate from the damaged ACL will be recovered from the hydrogel and investigated by biological and immunological criteria to determine to what degree they share the properties of MSCs. Their location within the ACL will be determined by immunohistochemistry. In Specific Aim 2, the responses of therse cells to a selected sub-set of growth factors will be determined. These factors are: FGF-2, BMP-12, BMP-13 and TGF-beta1. Both adenovirus- mediated gene transfer and, where possible, recombinant proteins will be evaluated in monolayer culture and in an in vitro "gap" model of ACL injury and repair. In Specific Aim 3, a full thickness, ACL rupture model in the pig will be used to determine the mechanical strength that is achievable when a gene-laden, reinforced hydrogel is used to repair a clinically-relevant defect. MRI, histology and immunohistochemistry will also be used to evaluate the healed ligament. These studies will advance our knowledge of the biology of the injured ACL and suggest novel, biologically-based approaches to healing.
描述(由申请人提供):每年有超过100,000例患者发生前交叉韧带(ACL)断裂。它不能自行愈合。由于手术修复和非手术治疗均不能提供可靠满意的临床结局,ACL断裂仍然是一个紧迫的骨科问题。本提案中描述的研究旨在通过应用新的生物学方法改善ACL的修复。这些是基于最近的数据表明,与所接受的观点相反,当加强的胶原水凝胶插入韧带的切断端之间时,断裂的ACL产生愈合反应。这种反应的关键是细胞从受损韧带迁移到水凝胶中。初步数据表明,这些并不代表ACL细胞作为一个整体,但构成了一个独特的群体,共享许多间充质干细胞(MSC)的特性。为了实现临床上有用的修复,这些细胞必须分裂、分化成韧带细胞并形成具有足够机械强度的基质。本提案中描述的实验使用体外和体内猪模型解决了这些基本问题。在特定目标1中,从受损ACL迁移的细胞将从水凝胶中回收,并通过生物学和免疫学标准进行研究,以确定它们在多大程度上共享MSC的特性。它们在ACL内的位置将通过免疫组织化学确定。在具体目标2中,将确定这些细胞对选定的生长因子子集的反应。这些因子是:FGF-2、BMP-12、BMP-13和TGF-β 1。将在单层培养物和ACL损伤和修复的体外“间隙”模型中评价腺病毒介导的基因转移和重组蛋白(如可能)。在特定目标3中,猪的全层ACL断裂模型将用于确定当使用基因负载的增强水凝胶修复临床相关缺损时可实现的机械强度。MRI、组织学和免疫组织化学也将用于评价愈合的韧带。这些研究将推进我们对受伤ACL生物学的了解,并提出新的基于生物学的愈合方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTOPHER Howard EVANS其他文献
CHRISTOPHER Howard EVANS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTOPHER Howard EVANS', 18)}}的其他基金
Use of Chemically Modified RNA to Enhance Bone Healing
使用化学修饰的 RNA 来增强骨愈合
- 批准号:
10673114 - 财政年份:2019
- 资助金额:
$ 30.26万 - 项目类别:
Use of Chemically Modified RNA to Enhance Bone Healing
使用化学修饰的 RNA 来增强骨愈合
- 批准号:
10455541 - 财政年份:2019
- 资助金额:
$ 30.26万 - 项目类别:
Use of Chemically Modified RNA to Enhance Bone Healing
使用化学修饰的 RNA 来增强骨愈合
- 批准号:
9977933 - 财政年份:2019
- 资助金额:
$ 30.26万 - 项目类别:
Use of Chemically Modified RNA to Enhance Bone Healing
使用化学修饰的 RNA 来增强骨愈合
- 批准号:
10251257 - 财政年份:2019
- 资助金额:
$ 30.26万 - 项目类别:
Use of Chemically Modified RNA to Enhance Bone Healing
使用化学修饰的 RNA 来增强骨愈合
- 批准号:
9816200 - 财政年份:2019
- 资助金额:
$ 30.26万 - 项目类别:
2014 Musculoskeletal Biology and Bioengineering Gordon Research Conference & Gord
2014年肌肉骨骼生物学与生物工程戈登研究会议
- 批准号:
8707028 - 财政年份:2014
- 资助金额:
$ 30.26万 - 项目类别:
Novel, Rapidly Translatable Technologies for Healing Long Bone Segmental Defects
用于治疗长骨段缺损的新颖、快速可转化技术
- 批准号:
7943919 - 财政年份:2009
- 资助金额:
$ 30.26万 - 项目类别:
Novel, Rapidly Translatable Technologies for Healing Long Bone Segmental Defects
用于治疗长骨段缺损的新颖、快速可转化技术
- 批准号:
7843399 - 财政年份:2009
- 资助金额:
$ 30.26万 - 项目类别:
AAOS Multi-Year Research Symposia for 2006-2010
2006-2010 AAOS 多年研究研讨会
- 批准号:
7651403 - 财政年份:2006
- 资助金额:
$ 30.26万 - 项目类别:
相似国自然基金
基于sIgA的V(D)J结构多样性探索腺病毒载体鼻喷新冠奥密克戎疫苗诱导的呼吸道粘膜免疫原性特征
- 批准号:82302607
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
新型腺病毒载体Ad49L介导的高水平干扰素α抑制疫苗体液免疫的机制
- 批准号:82302001
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
新冠病毒灭活病毒疫苗及腺病毒载体疫苗序贯免疫保护作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:100.0 万元
- 项目类别:省市级项目
新型腺病毒载体丙型肝炎疫苗在狨猴模型中的免疫保护机制
- 批准号:n/a
- 批准年份:2022
- 资助金额:100.0 万元
- 项目类别:省市级项目
新型腺病毒载体疫苗长效免疫机制
- 批准号:
- 批准年份:2022
- 资助金额:53 万元
- 项目类别:面上项目
基于肠道腺病毒载体平台COVID-19粘膜疫苗的设计与筛选
- 批准号:82161138001
- 批准年份:2021
- 资助金额:150 万元
- 项目类别:国际(地区)合作与交流项目
非复制型4型腺病毒载体重组新冠疫苗的构建和免疫学评价研究
- 批准号:82101919
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
纳米蛋白冠突破腺病毒载体疫苗预存免疫效应研究
- 批准号:
- 批准年份:2021
- 资助金额:56 万元
- 项目类别:面上项目
腺病毒载体新冠疫苗与灭活新冠疫苗诱导的免疫应答特征及序贯免疫策略研究
- 批准号:
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
基于黑猩猩腺病毒载体的新型冠状病毒疫苗研究
- 批准号:32070926
- 批准年份:2020
- 资助金额:58 万元
- 项目类别:面上项目
相似海外基金
Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
- 批准号:
19K09482 - 财政年份:2019
- 资助金额:
$ 30.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
- 批准号:
2273599 - 财政年份:2019
- 资助金额:
$ 30.26万 - 项目类别:
Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
- 批准号:
18K14964 - 财政年份:2018
- 资助金额:
$ 30.26万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
- 批准号:
16K18873 - 财政年份:2016
- 资助金额:
$ 30.26万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
- 批准号:
9193681 - 财政年份:2016
- 资助金额:
$ 30.26万 - 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
- 批准号:
15K18939 - 财政年份:2015
- 资助金额:
$ 30.26万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
- 批准号:
26450450 - 财政年份:2014
- 资助金额:
$ 30.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
- 批准号:
26462183 - 财政年份:2014
- 资助金额:
$ 30.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
- 批准号:
26893253 - 财政年份:2014
- 资助金额:
$ 30.26万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
- 批准号:
24701021 - 财政年份:2012
- 资助金额:
$ 30.26万 - 项目类别:
Grant-in-Aid for Young Scientists (B)